Arch Therapeutics : Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
February 25, 2021 at 05:35 pm
Share
FORM D
Notice of Exempt Offering of Securities
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.
OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0
1. Issuer's Identity
CIK (Filer ID Number)
Previous Name(s)
None
Entity Type
0001537561
ALMAH, INC
Almah, Inc.
ALMAH,INC
Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other
Name of Issuer
Arch Therapeutics, Inc.
Jurisdiction of Incorporation/Organization
NEVADA
Year of Incorporation/Organization
Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed
2. Principal Place of Business and Contact Information
Name of Issuer
Arch Therapeutics, Inc.
Street Address 1
Street Address 2
235 WALNUT STREET, SUITE 6
City
State/Province/Country
ZIP/Postal Code
Phone No. of Issuer
FRAMINGHAM
MASSACHUSETTS
01702
617-431-2313
3. Related Persons
Last Name
First Name
Middle Name
Norchi
Terrence
W.
Street Address 1
Street Address 2
235 Walnut Street, Suite 6
City
State/Province/Country
ZIP/Postal Code
Framingham
MASSACHUSETTS
01702
Relationship:
Executive Officer
Director
Promoter
Clarification of Response (if Necessary)
Last Name
First Name
Middle Name
Dhillon
Punit
Street Address 1
Street Address 2
235 Walnut Street, Suite 6
City
State/Province/Country
ZIP/Postal Code
Framingham
MASSACHUSETTS
01702
Relationship:
Executive Officer
Director
Promoter
Clarification of Response (if Necessary)
Last Name
First Name
Middle Name
Sulat
James
R.
Street Address 1
Street Address 2
235 Walnut Street, Suite 6
City
State/Province/Country
ZIP/Postal Code
Framingham
MASSACHUSETTS
01702
Relationship:
Executive Officer
Director
Promoter
Clarification of Response (if Necessary)
Last Name
First Name
Middle Name
Davis
Richard
E.
Street Address 1
Street Address 2
235 Walnut Street, Suite 6
City
State/Province/Country
ZIP/Postal Code
Framingham
MASSACHUSETTS
01702
Relationship:
Executive Officer
Director
Promoter
Clarification of Response (if Necessary)
4. Industry Group
Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
Pharmaceuticals
Other Health Care
Manufacturing
Real Estate
Commercial
Construction
REITS & Finance
Residential
Other Real Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
Other
5. Issuer Size
Revenue Range
Aggregate Net Asset Value Range
No Revenues
No Aggregate Net Asset Value
$1 - $1,000,000
$1 - $5,000,000
$1,000,001 - $5,000,000
$5,000,001 - $25,000,000
$5,000,001 - $25,000,000
$25,000,001 - $50,000,000
$25,000,001 - $100,000,000
$50,000,001 - $100,000,000
Over $100,000,000
Over $100,000,000
Decline to Disclose
Decline to Disclose
Not Applicable
Not Applicable
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 505
Rule 504 (b)(1)(i)
Rule 506(b)
Rule 504 (b)(1)(ii)
Rule 506(c)
Rule 504 (b)(1)(iii)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
7. Type of Filing
New Notice
Date of First Sale
2021-02-11
First Sale Yet to Occur
Amendment
8. Duration of Offering
Does the Issuer intend this offering to last more than one year?
Yes
No
9. Type(s) of Securities Offered (select all that apply)
Pooled Investment Fund Interests
Equity
Tenant-in-Common Securities
Debt
Mineral Property Securities
Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
Other (describe)
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes
No
Clarification of Response (if Necessary)
11. Minimum Investment
Minimum investment accepted from any outside investor
$
0
USD
12. Sales Compensation
Recipient
Recipient CRD Number
None
H.C. Wainwright & Co.
375
(Associated) Broker or Dealer
None
(Associated) Broker or Dealer CRD Number
None
Street Address 1
Street Address 2
430 PARK AVENUE, 4TH FLOOR
City
State/Province/Country
ZIP/Postal Code
NEW YORK
NEW YORK
10022
State(s) of Solicitation
All States
Foreign/Non-US
13. Offering and Sales Amounts
Total Offering Amount
$
7520000
USD
Indefinite
Total Amount Sold
$
6900000
USD
Total Remaining to be Sold
$
620000
USD
Indefinite
Clarification of Response (if Necessary)
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
9
15. Sales Commissions & Finders' Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions
$
492750
USD
Estimate
Finders' Fees
$
0
USD
Estimate
Clarification of Response (if Necessary)
Excludes value of warrants to purchase up to 3,234,375 shares at an exercise price of $0.20 per share
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
$
0
USD
Estimate
Clarification of Response (if Necessary)
Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Terms of Submission
In submitting this notice, each Issuer named above is:
Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).
Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
Issuer
Signature
Name of Signer
Title
Date
Arch Therapeutics, Inc.
/s/ Terrrence Norchi
Terrence Norchi
President, Chief Executive Officer
2021-02-25
Attachments
Original document
Permalink
Disclaimer
Arch Therapeutics Inc. published this content on 25 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 February 2021 17:35:01 UTC.
Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Companyâs flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.
Arch Therapeutics : Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.